健脾益肺颗粒联合布地奈德福莫特罗治疗慢性阻塞性肺疾病临床研究  

Clinical Study on the Combination of Jianpi Yifei Granules and Budesonide Fomotro in the Treatment of Chronic Obstructive Pulmonary Disease

作　　者：朱美君 孙芳 余震坤 陈洋[3] ZHU Meijun;SUN Fang;YU Zhenkun;CHEN Yang(Shanyang County People s Hospital,Shaanxi Shangluo 726100,China;Xunyi County Hospital,Shaanxi Xianyang 711300,China;Shangluo Central Hospital,Shaanxi Shangluo 726000,China)

机构地区：[1]山阳县人民医院,陕西商洛726100 [2]旬邑县医院,陕西咸阳711300 [3]商洛市中心医院,陕西商洛726000

出　　处：《现代中医药》2024年第1期51-55,共5页Modern Chinese Medicine

基　　金：白求恩•医学科学研究基金资助项目(SCZ415BN)。

摘　　要：目的观察健脾益肺颗粒联合布地奈德福莫特罗对慢性阻塞性肺疾病的治疗效果。方法将90例患者分成对照组45例和治疗组45例。对照组雾化吸入布地奈德福莫特罗治疗。治疗组患者在对照组基础上,口服健脾益肺颗粒。对比两组患者在治疗3个月后的总有效率、不良反应的发生情况、圣乔治呼吸量表(St.George s Respiratory Scale,SGRQ)。检测两组患者的诱导痰炎症指标[前列腺素E2(Prostaglandin E2,PEG2)、白细胞介素6(Interleukin 6,IL-6)、白细胞介素17(Interleukin 17,IL-17)]和主要肺功能指标[一秒钟用力呼气容积/用力肺活量(Forced expiratory volume per second/forced vital capacity,FEV1/FVC)、FEV1%预计值、最大呼气流量(peak expiratory flow,PEF)]的水平。结果治疗组患者在治疗后的总有效率为95.56%,明显高于对照组的80.00%,差异有统计学意义(P<0.05)。两组治疗后的病情程度(SGRQ评分)显著减轻,且治疗组降低更明显(P<0.05)。治疗后,两组的诱导痰PEG2、IL-6、IL-17明显降低,FEV1/FVC、FEV1%预计值、PEF均显著升高(P<0.05);治疗组诱导痰PEG2、IL-6、IL-17比对照组低,FEV1/FVC、FEV1%预计值、PEF比对照组高,差异有统计学意义(P<0.05)。两组的药物主要不良反应发生率无明显差异(P>0.05)。结论健脾益肺颗粒联合布地奈德福莫特罗治疗慢性阻塞性肺疾病,有助于控制病情,减轻患者气道炎症反应,提高肺功能。Objective To explore the therapeutic effect of Jianpi Yifei granules combined with Budesonide Fomotro on chronic obstructive pulmonary disease.Methods All 90 patients were divided into a control group of 45 cases and a treatment group of 45 cases.The control group was treated with nebulized inhalation of budesonide and formoterol.On the basis of the control group,patients in the treatment group received oral administration of Jianpi Yifei granules.Compare the total effective rate,incidence of adverse reactions,and St.George s Respiratory Scale(SGRQ)between two groups of patients after 3 months of treatment.Detect the induced sputum inflammation indicators[Prostaglandin E2(PEG2),Interleukin 6(IL-6),Interleukin 17(IL-17)],and major lung function indicators[Forced expiratory volume per second/forced vital capacity(FEV1/FVC),FEV1%estimated value,peak expiratory flow(PEF)]in two groups of patients.Results The total effective rate of the treatment group patients after treatment was 95.56%,which was significantly higher than the 80.00%of the control group,and the difference was statistically significant(P<0.05).The severity of the condition(SGRQ score)significantly improved in both groups after treatment,and the decrease was more significant in the treatment group(P<0.05).After treatment,the induced sputum PEG2,IL-6,and IL-17 in both groups were significantly reduced,while FEV1/FVC,FEV1%predicted value,and PEF were significantly increased(P<0.05);The induced sputum PEG2,IL-6,and IL-17 in the treatment group were lower than those in the control group,while FEV1/FVC,FEV1%predicted value,and PEF were higher than those in the control group,with statistically significant differences(P<0.05).There was no significant difference in the incidence of major adverse reactions between the two groups of drugs(P>0.05).Conclusion The combination of Jianpi Yifei granules and Budesonide Fomotro is effective in treating chronic obstructive pulmonary disease,helping to control the condition,reduce airway inflammation,and improve lung funct

关 键 词：健脾益肺颗粒 布地奈德福莫特罗 慢性阻塞性肺疾病 病情 气道炎症反应 肺功能 

分 类 号：R256.1[医药卫生—中医内科学]